DEMANT:OMXCOPDemant A/S Analysis
Data as of 2026-03-15 - not real-time
DKK 188.10
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
The stock is trading at DKK 188.1, just above the 20‑day SMA of 188.06 but well below the 50‑day (203.57) and 200‑day (232.20) averages, indicating a short‑term pull‑back within a broader bearish trend. Momentum is mixed: the RSI sits at 45, suggesting neutral pressure, while the MACD histogram turned positive and the MACD line crossed above its signal, a bullish technical signal. Price remains above the identified support of 175 and below the resistance near 199, giving a modest upside window on the near term.
Fundamentally, Demant delivers solid revenue growth of 3.4% and strong gross margins (~75%), yet its profit margin is modest at 6.7% and debt levels are high, with a debt‑to‑equity ratio exceeding 200%. The DCF‑derived fair value of 151.5 is well under the current market price, implying the stock is overvalued relative to intrinsic estimates. Despite a healthy ROE of 24% and robust free cash flow, the lack of dividend payout and a forward PE of 12.75 point to a value‑oriented profile, while analyst consensus remains a “buy” with a median target near DKK 230.
Fundamentally, Demant delivers solid revenue growth of 3.4% and strong gross margins (~75%), yet its profit margin is modest at 6.7% and debt levels are high, with a debt‑to‑equity ratio exceeding 200%. The DCF‑derived fair value of 151.5 is well under the current market price, implying the stock is overvalued relative to intrinsic estimates. Despite a healthy ROE of 24% and robust free cash flow, the lack of dividend payout and a forward PE of 12.75 point to a value‑oriented profile, while analyst consensus remains a “buy” with a median target near DKK 230.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Bullish MACD crossover
- Price above 20‑day SMA and near support
- Neutral RSI offering upside potential
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Valuation gap between market price and DCF fair value
- Strong operating and free cash flow
- Elevated leverage increasing financial risk
Long Term
> 3 yearsCautious
Model confidence: 8/10
Key Factors
- Current price significantly above intrinsic fair value
- High debt‑to‑equity ratio limiting future flexibility
- Potential regulatory headwinds in the medical‑device sector
Key Metrics & Analysis
Financial Health
Revenue Growth3.40%
Profit Margin6.73%
P/E Ratio16.8
ROE24.20%
ROA6.93%
Debt/Equity211.59
P/B Ratio4.0
Op. Cash FlowDKK4.0B
Free Cash FlowDKK3.3B
Industry P/E26.2
Technical Analysis
TrendBearish
RSI45.1
SupportDKK 175.00
ResistanceDKK 199.00
MA 20DKK 188.06
MA 50DKK 203.57
MA 200DKK 232.20
MACDBullish
VolumeDecreasing
Fear & Greed Index72.88
Valuation
Fair ValueDKK 151.50
Target PriceDKK 232.17
Upside/Downside23.43%
GradeOvervalued
TypeValue
Risk Assessment
Beta0.43
Volatility48.56%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.